<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462590</url>
  </required_header>
  <id_info>
    <org_study_id>27022015</org_study_id>
    <nct_id>NCT02462590</nct_id>
  </id_info>
  <brief_title>Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial</brief_title>
  <acronym>PROSPECT</acronym>
  <official_title>Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics are commercially available live bacteria thought to have health benefits when
      ingested. A literature review of probiotic studies in the intensive care unit (ICU) found
      that in patients who receive probiotics, there is a 25% reduction in lung infection, known as
      ventilator-associated pneumonia (VAP). There is also an 18% reduction in the chance of
      developing any infection in the ICU. However, the studies reviewed were small and not well
      done. Therefore, whether probiotics are really helpful or not is unclear. Before a large
      carefully performed study is done to evaluate the effects of probiotics in critically ill
      patients, a pilot trial was needed. The Investigators completed a multicenter pilot RCT for
      which the primary outcomes relate to feasibility. Feasibility goals were met. 1) Recruitment
      for the Pilot was achieved in 1 year; 2) Adherence to the protocol was 96%; 3) There were no
      cases of contamination; 4) The VAP rate was 15%. This study is very important in the ongoing
      search for more effective strategies to prevent serious infection during critical illness.
      Probiotics may be an easy-to-use, readily available, inexpensive approach to help future
      critically ill patients around the world.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:Probiotics are live microorganisms thought to have health benefits when ingested.
      Randomized controlled trials (RCTs) have documented favourable impact on a range of clinical
      problems, including prevention of upper respiratory tract infections, antibiotic-associated
      diarrhea, Clostridium difficile-associated diarrhea, and irritable bowel syndrome. Our recent
      meta-analysis of probiotic RCTs in the intensive care unit (ICU) also suggests 25% lower
      rates of ventilator-associated pneumonia (VAP) and 18% lower infection rates overall when
      administered to critically ill mechanically ventilated patients. However, these estimates
      arise from small, modest quality single-center RCTs yielding imprecise estimates of effect
      and uncertain generalizability, and require confirmation in a large methodologically
      rigourous RCT. Before launching a complex costly RCT testing whether probiotics confer
      benefit, harm, or have no impact on infectious and non-infectious outcomes, a pilot trial was
      needed. The investigators completed a multicenter pilot RCT for which the primary outcomes
      relate to feasibility: 1) recruitment success in 1 year; 2) &gt;90% adherence to the probiotic
      protocol; 3) &lt;5% contamination; 4) an estimated VAP rate. Patients have been randomized in 14
      centers in Canada and the US, with an informed consent rate of 84%. Feasibility goals were
      met. 1) Recruitment for the Pilot was achieved in 1 year; 2) Adherence to the protocol was
      96%; 3) There were no cases of contamination; 4) The VAP rate was 15%. This will be an
      internal Pilot which will be incorporated into the main trial.

      Setting: 13 ICUs in Canada, 2 ICUs in United States

      Methods: Patients age 18 years or older, admitted to the ICU, with an anticipated duration of
      ventilation of ≥72 hours are included. Patients are excluded if they have increased risk of
      iatrogenic probiotic infection or endovascular infection, primary diagnosis of severe acute
      pancreatitis, percutaneous gastric or jejunal feeding tubes already in situe, strict
      contraindication or inability to receive enteral medications, have hopeless prognosis,
      withholding or withdrawal of advanced life support is planned, or if previous enrolment in
      this or a related trial. Following informed consent, patients are randomized in variable
      unspecified block sizes in a fixed allocation ratio of 1:1, stratified by ICU and
      medical/surgical/trauma status. Twice daily, patients receive either 1x1010 colony forming
      units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an
      identical placebo capsule. Both are suspended in water administered via nasogastric tube or
      by capsule. Research Nurses notify local Study Pharmacists after obtaining informed consent.
      Study Pharmacists obtain the allocation from the PROSPECT website. Only the Database Manager
      and Study Pharmacists will have access to the randomization schedule; everyone else remains
      blinded. Patients receive the intervention until:1) ICU discharge; 2) death; or 3) isolation
      of Lactobacillus spp. in a sterile site, or if cultured as the sole or predominant organism
      from a non-sterile site.

      RCT Trial Outcomes: The primary outcome is VAP; secondary outcomes include ICU-acquired
      infections, diarrhea (total, antibiotic-associated and CDAD), antibiotic use, length of stay
      and mortality in the ICU and hospital, and acquired L. rhamnosus GG infections.

      Relevance: Despite clinical uptake of some existing VAP prevention strategies, the morbidity,
      mortality and cost of VAP underscore the need for further cost-effective interventions to
      reduce its impact. Whether probiotics impact on VAP, other infections such as CDAD,
      antibiotic-associated diarrhea or antibiotic use is unclear. When rigorously evaluated,
      probiotics may have salutary effects decreasing nosocomial infections as prior RCTs suggest;
      alternatively, probiotics may have no demonstrable effect, or actually cause infections in
      critically ill patients with impaired immune function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Ventilator Associated Pneumonia (VAP)</measure>
    <time_frame>60 Days</time_frame>
    <description>VAP will be diagnosed clinically at each site in patients who are receiving invasive mechanical ventilation for at least 48 hours, when there is a new, progressive or persistent radiographic infiltrate with no other obvious cause and the presence of any 2 of the following symptoms or signs: 1) fever (temperature &gt;38°C) or hypothermia (temperature &lt;36°C as measured by core body temperature); 2) relative neutropenia (&lt;3.0 x 106/L) or leukocytosis (&gt;10 x 106/L) and 3) purulent sputum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with infections acquired during the ICU stay</measure>
    <time_frame>60 Days</time_frame>
    <description>Any infection acquired during the ICU stay, defined as respiratory or other infections including bloodstream infections, intravascular catheter-related sepsis, intra-abdominal infections, urosepsis and surgical wound infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Clostridium Difficile-associated diarrhea</measure>
    <time_frame>60 Days</time_frame>
    <description>3 or more episodes of unformed stools in ≤24 hours and C. difficile toxin positive stool or colonoscopic or histopathologic findings demonstrating pseudomembranous colitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with antibiotic-associated diarrhea</measure>
    <time_frame>60 Days</time_frame>
    <description>Antibiotic-associated diarrhea and defined as more than 2 liquid stools a day for 3 or more days in quantities in excess of normal for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with diarrhea</measure>
    <time_frame>60 Days</time_frame>
    <description>Diarrhea defined as 3 or more loose or watery bowel movements, according to the Bristol Stool Chart (type 6 or 7) and use of a fecal management device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defined Daily Dose Antibiotic Exposure</measure>
    <time_frame>60 Days</time_frame>
    <description>Defined daily dose (DDD), daily doses of therapy (DOT), and antibiotic-free days in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>60 Days</time_frame>
    <description>Endotracheal tube or tracheostomy, length of ICU stay and length of hospital stay: recorded as number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality and in-hospital mortality:</measure>
    <time_frame>60 Days</time_frame>
    <description>ICU mortality and in-hospital mortality recorded at ICU discharge and hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2650</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <condition>Infections</condition>
  <condition>C-Difficile</condition>
  <condition>Antibiotic-associated Diarrhea</condition>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Lactobacillus rhamnosus GG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population [Morrow 2010]. This has also been used successfully in the PROSPECT Pilot Trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L. rhamnosus GG - Probiotic</intervention_name>
    <description>Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule</description>
    <arm_group_label>Lactobacillus rhamnosus GG</arm_group_label>
    <other_name>Culturelle Probiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Microcrystalline Cellulose</intervention_name>
    <description>Microcrystalline Cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults ≥ 18 years of age

          2. Admitted to any ICU and receiving invasive mechanical ventilation

          3. Anticipated ventilation of ≥72 hours at the time of screening, as per the ICU
             physician.

        Exclusion Criteria:

          1. Invasively mechanically ventilated &gt;72 hours at the time of screening;

          2. Patients at potential increased risk of iatrogenic probiotic infection (see Section
             2.6 for detailed explanation) including specific immunocompromised populations (HIV
             &lt;200 CD4 cells/μL, those receiving chronic immunosuppressive medications (e.g.,
             azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate,
             Anti-IL2), previous transplantation (including stem cell) at any time, malignancy
             requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count &lt;
             500]). However, patients receiving corticosteroids previously or presently or
             projected to receive corticosteroids are not excluded;

          3. Patients at risk for endovascular infection (previously documented rheumatic heart
             disease, congenital valve disease, surgically repaired congenital heart disease,
             unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic
             material [mechanical or bio-prosthetic cardiac valves], previous or current
             endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic
             aneurysm repair, stents involving large arteries such as aorta, femorals and
             carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not
             short-term) hemodialysis catheters, pacemakers or defibrillators. Patients with
             temporary central venous catheters, central venous dialysis catheters or peripherally
             inserted central catheters (PICCs) are not excluded and patients with coronary artery
             stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded;
             patients with mitral valve prolapse or bicuspid aortic valve are not excluded
             providing they have no other exclusion criteria;

          4. Patients with a primary diagnosis of severe acute pancreatitis, without reference to a
             Ranson score [Ranson 1974]). However, patients with mild or moderate pancreatitis are
             not excluded;

          5. Patients with percutaneous gastric or jejunal feeding tubes already in situ as per
             Health Canada guidance;

          6. Strict contraindication or inability to receive enteral medications;

          7. Intent to withdraw advanced life support as per the ICU physician;

          8. Previous enrolment in this or current enrolment in a potentially confounding tria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah J Cook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Zytaruk</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>35325</phone_ext>
    <email>zytaruk@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Peter Louheed Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Stelfox, MD</last_name>
      <phone>403-944-8748</phone>
      <email>tstelfox@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Joshua Booth</last_name>
      <phone>403-944-8748</phone>
      <email>Joshua.Booth@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Tom Stelfox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sligl, MD</last_name>
      <phone>780-492-9951</phone>
      <email>wsligl@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lorena McCoshen</last_name>
      <phone>780-492-9951</phone>
      <email>Lorena.Mccoshen@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Wendy Sligl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbia Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Reynolds, MD</last_name>
      <phone>604-520-4695</phone>
      <email>sreynolds.md@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Suzette Williams</last_name>
      <phone>604-520-4695</phone>
      <email>Suzette.Willems@fraserhealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Reynolds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Foster, RN, CCRP</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>68336</phone_ext>
      <email>denise.foster@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Bill Henderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Alcuaz</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>66015</phone_ext>
      <email>valcuaz@cheos.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Dodek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver Island Health Authority</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Auld</last_name>
      <phone>250-370-8111</phone>
      <phone_ext>12847</phone_ext>
      <email>Fiona.Auld@viha.ca</email>
    </contact>
    <investigator>
      <last_name>Gordon Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Ovakim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Marten</last_name>
      <phone>204-235-3223</phone>
      <email>NMARTEN@sbgh.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Ryan Zarychanski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII</name>
      <address>
        <city>Halfax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Julien</last_name>
      <phone>902-473-7883</phone>
      <email>lisa.julien@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Rick Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Osler Brampton - Brampton Civic Hospital</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Trop, MD</last_name>
      <phone>905-494-2120</phone>
      <email>sebastien.trop@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zaynab Panchbhaya</last_name>
      <phone>905-494-2120</phone>
      <email>Zaynab.Panchbhaya@williamoslerhs.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sebastien Trop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brantford General Hospital</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Bento</last_name>
      <email>bento.karen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Brenda Reeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joseph Brant Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7S 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Lysecki, MD</last_name>
      <phone>905-632-3737</phone>
      <email>paul.lysecki@medportal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Campbell, MSc</last_name>
      <phone>905-632-3737</phone>
      <email>TCampbell@josephbranthospital.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Lysecki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Ontario</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Kutsogiannis, Dr</last_name>
      <phone>(780) 735-4111</phone>
      <email>djk3@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Tompson, Ms</last_name>
      <phone>(780) 735-4111</phone>
      <email>Patrica.Thompson@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Kutsogiannis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Science Centre - Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Hand</last_name>
      <phone>905-972-1294</phone>
      <email>Handlori@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Maureen Meade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>France Clarke</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>33633</phone_ext>
      <email>clarkef@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Deborah J Cook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Science Centre - Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Millen</last_name>
      <phone>905-719-6133</phone>
      <email>millent@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Timothy Kirachi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Hunt</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>3190</phone_ext>
      <email>huntm4@KGH.KARI.NET</email>
    </contact>
    <investigator>
      <last_name>John Muscedere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Hosek, MD</last_name>
      <phone>519-588-0331</phone>
      <email>paul.hosek@grhosp.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Jesso, NP</last_name>
      <phone>519-588-0331</phone>
      <email>rebecca.jesso@grhosp.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Hosek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LHSC - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Bentall</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32546</phone_ext>
      <email>traceyc.bentall@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Ian Ball, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LHSC - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Campbell</last_name>
      <email>Eileen.Campbell@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Ian Ball, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Watpool</last_name>
      <phone>613-737-8724</phone>
      <email>iwatpool@ottawahospital.on.ca</email>
    </contact>
    <investigator>
      <last_name>Lauralyn McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Civic Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigette Gomes</last_name>
      <email>bgomes@toh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Joe Pagilarello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niagara Health - St. Catharine's Hospital</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Tsang, MD</last_name>
      <phone>905-387-4647</phone>
      <email>jennifer.tsang@mail.utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bev Richter</last_name>
      <phone>905-387-4647</phone>
      <email>Beverley.Richter@niagarahealth.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Tsang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neill Adhikari, MD</last_name>
      <phone>(416) 480-6100</phone>
      <email>Neill.Adhikari@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Marinoff, RN</last_name>
      <phone>(416) 480-6100</phone>
      <email>Nicole.Marinoff@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Neill Adhikari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orla Smith</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>3179</phone_ext>
      <email>smitho@smh.toronto.on.ca</email>
    </contact>
    <investigator>
      <last_name>John Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumesh Shah, CCRP</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>8445</phone_ext>
      <email>SShah@mtsinai.on.ca</email>
    </contact>
    <investigator>
      <last_name>Geeta Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UHN - Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph`s Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennie Johnstone</last_name>
      <email>johnsj48@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Rob Cirone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Lellouche, MD</last_name>
      <phone>418-656-8711</phone>
      <email>francois.lellouche@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Lizotte</last_name>
      <phone>418-656-8711</phone>
      <email>patricia.lizotte@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Francois Lellouche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel-Dieu de Lévis</name>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Archambault, MD</last_name>
      <phone>418-835-7121</phone>
      <email>patrick.m.archambault@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maude Dionne</last_name>
      <phone>418-835-7121</phone>
      <email>wikiteam.cisssca@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Archambault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center Hospital University Montreal (NCHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Lebrasseur</last_name>
      <phone>514-890-8000</phone>
      <email>martine.lebrasseaur.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Martin Girard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josie Campisi</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>42408</phone_ext>
      <email>Josie.Campisi@MUHC.MCGILL.CA</email>
    </contact>
    <investigator>
      <last_name>Kosar Khwaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josie Campisi</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>65542</phone_ext>
      <email>Josie.Campisi@MUHC.MCGILL.CA</email>
    </contact>
    <investigator>
      <last_name>Arnie Kristof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacre Coeur Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Williams</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3487</phone_ext>
      <email>eresi@crhsc.rtss.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Charbonney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Marquis, MD</last_name>
      <phone>514-252-6400</phone>
      <phone_ext>4679</phone_ext>
      <email>f.marquis@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Danae Tassey</last_name>
      <phone>514-252-6400</phone>
      <phone_ext>4679</phone_ext>
      <email>danae.tassy.cemtl@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Francois Marquis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Enfant-Jesus, CHU de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Claude Tremblay, B.Sc</last_name>
      <phone>418-649-0252</phone>
      <phone_ext>6060</phone_ext>
      <email>Marie-Claude.Tremblay@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Lauzier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sherbrooke Hospital</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Helen Masse</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>14173</phone_ext>
      <email>mhmasse.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Lamontagne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Ventilator Associated Pneumonia</keyword>
  <keyword>Infections</keyword>
  <keyword>C-Difficile</keyword>
  <keyword>Antibiotic-associated Diarrhea</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

